ATE305001T1 - Propansäure-derivate als integrin-rezeptor- antagonisten - Google Patents
Propansäure-derivate als integrin-rezeptor- antagonistenInfo
- Publication number
- ATE305001T1 ATE305001T1 AT01936253T AT01936253T ATE305001T1 AT E305001 T1 ATE305001 T1 AT E305001T1 AT 01936253 T AT01936253 T AT 01936253T AT 01936253 T AT01936253 T AT 01936253T AT E305001 T1 ATE305001 T1 AT E305001T1
- Authority
- AT
- Austria
- Prior art keywords
- acid derivatives
- propanoic acid
- receptor antagonists
- integrin receptor
- integrin
- Prior art date
Links
- 229940127449 Integrin Receptor Antagonists Drugs 0.000 title 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/12—Nitrogen atoms not forming part of a nitro radical
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0011817.4A GB0011817D0 (en) | 2000-05-16 | 2000-05-16 | Antagonists of integrin receptors |
| PCT/EP2001/004472 WO2001087840A1 (en) | 2000-05-16 | 2001-04-19 | Propanoic acid derivatives as integrin receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE305001T1 true ATE305001T1 (de) | 2005-10-15 |
Family
ID=9891715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01936253T ATE305001T1 (de) | 2000-05-16 | 2001-04-19 | Propansäure-derivate als integrin-rezeptor- antagonisten |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6974828B2 (de) |
| EP (1) | EP1282602B1 (de) |
| JP (1) | JP2003533511A (de) |
| AR (1) | AR032327A1 (de) |
| AT (1) | ATE305001T1 (de) |
| AU (1) | AU6221201A (de) |
| DE (1) | DE60113525T2 (de) |
| ES (1) | ES2248333T3 (de) |
| GB (1) | GB0011817D0 (de) |
| WO (1) | WO2001087840A1 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2544678C (en) | 2003-11-05 | 2013-12-31 | Sunesis Pharmaceuticals, Inc. | Modulators of cellular adhesion |
| DK2444079T3 (en) | 2005-05-17 | 2017-01-30 | Sarcode Bioscience Inc | Compositions and Methods for the Treatment of Eye Diseases |
| ES2830024T3 (es) | 2007-10-19 | 2021-06-02 | Novartis Ag | Composiciones y métodos para el tratamiento del edema macular |
| EP2730282A1 (de) | 2007-11-08 | 2014-05-14 | The General Hospital Corporation | Verfahren und Zusammensetzung zur Behandlung von Proteinurie-Erkrankungen |
| WO2009139817A2 (en) | 2008-04-15 | 2009-11-19 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
| WO2011050175A1 (en) | 2009-10-21 | 2011-04-28 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
| US8783251B2 (en) * | 2010-02-12 | 2014-07-22 | Piper Medical, Inc | Enhanced manually actuated pressure controlled modulator technology |
| KR20200108932A (ko) | 2012-07-25 | 2020-09-21 | 에스에이알코드 바이오사이언스 인코포레이티드 | Lfa-1 저해제 및 그의 다형체 |
| PT2953948T (pt) | 2013-02-07 | 2017-12-12 | Scifluor Life Sciences Inc | Antagonistas de integrina fluorada |
| US8901144B2 (en) | 2013-02-07 | 2014-12-02 | Scifluor Life Sciences, Llc | Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives |
| US9790222B2 (en) | 2015-02-19 | 2017-10-17 | Scifluor Life Sciences, Inc. | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69710319T2 (de) * | 1996-03-29 | 2002-08-14 | G.D. SEARLE & CO., CHICAGO | Para-substituierte phenylpropansäure derivate als integrin-antagonisten |
| DE69706407T2 (de) | 1996-03-29 | 2002-05-29 | G.D. Searle & Co., Chicago | META-SUBSTITUIERTE PHENYLENDERIVATE UND IHRE VERWENDUNG ALS ALPHAvBETA3 INTERGRIN-ANTAGONISTEN ODER INHIBITOREN |
| NZ333904A (en) * | 1996-07-25 | 2000-06-23 | Biogen Inc | VLA-4 and IIb/IIIa cell adhesion inhibitors |
-
2000
- 2000-05-16 GB GBGB0011817.4A patent/GB0011817D0/en not_active Ceased
-
2001
- 2001-04-19 AU AU62212/01A patent/AU6221201A/en not_active Abandoned
- 2001-04-19 ES ES01936253T patent/ES2248333T3/es not_active Expired - Lifetime
- 2001-04-19 US US10/258,584 patent/US6974828B2/en not_active Expired - Fee Related
- 2001-04-19 EP EP01936253A patent/EP1282602B1/de not_active Expired - Lifetime
- 2001-04-19 DE DE60113525T patent/DE60113525T2/de not_active Expired - Fee Related
- 2001-04-19 AT AT01936253T patent/ATE305001T1/de not_active IP Right Cessation
- 2001-04-19 JP JP2001584236A patent/JP2003533511A/ja not_active Withdrawn
- 2001-04-19 WO PCT/EP2001/004472 patent/WO2001087840A1/en not_active Ceased
- 2001-05-14 AR ARP010102270A patent/AR032327A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2248333T3 (es) | 2006-03-16 |
| GB0011817D0 (en) | 2000-07-05 |
| WO2001087840A1 (en) | 2001-11-22 |
| US6974828B2 (en) | 2005-12-13 |
| DE60113525D1 (de) | 2006-02-02 |
| US20030144311A1 (en) | 2003-07-31 |
| EP1282602B1 (de) | 2005-09-21 |
| JP2003533511A (ja) | 2003-11-11 |
| AR032327A1 (es) | 2003-11-05 |
| AU6221201A (en) | 2001-11-26 |
| DE60113525T2 (de) | 2006-06-22 |
| EP1282602A1 (de) | 2003-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE288898T1 (de) | Phenylethenyl- oder phenylethinylderivate als glutamatrezeptorantagonisten | |
| DE60120419D1 (de) | 4-phenyl-pyridin-derivate verwendbar als neurokinin-1 rezeptor antagonisten | |
| DE60021370D1 (de) | Piperazinderivate verwendbar als ccr5 antagonisten | |
| ATE374191T1 (de) | Urea derivate als integrin alpha 4 antagonisten | |
| DE60023167D1 (de) | Pyrazol-derivate als cannabinoidrezeptor-antagonisten | |
| DE60318697D1 (de) | Triazolderivate als tachykininrezeptor-antagonisten | |
| DE60021371D1 (de) | Piperidinderivate verwendbar als ccr5 antagonisten | |
| ATE259363T1 (de) | Piperazinderivate als 5-ht1b antagonisten | |
| NO20032861D0 (no) | Heteroarylurea nevropeptid YY5-reseptorantagonister | |
| ATE368659T1 (de) | Thrombinrezeptorantagonisten | |
| ATE389648T1 (de) | 4-(heterocyclylsulfonamido)-5-methoxy-6-(2- methoxyphenoxy)-2-phenyl- oder pyridylpyrimidine als endothelinrezeptorantagonisten | |
| DE50002364D1 (de) | Abgewandelte aminosäureamide als cgrp antagonisten | |
| DE60106607D1 (de) | Substituierte 1-aminoalkyl-lactame und ihre verwendung als muscarinrezeptor antagonisten | |
| DE60118569D1 (de) | 4-phenylpyridin-derivate als neurokinin-1-rezeptor-antagonisten | |
| EP1194151A4 (de) | Antagonisten der integrin rezeptoren | |
| ATE400554T1 (de) | 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives als muskarin-rezeptor antagonisten | |
| DE60114852D1 (de) | Chinazolin-derivate als alpha-1 adrenerge antagonisten | |
| DE60316411D1 (de) | Thiazolderivate als npy-rezeptorantagonisten | |
| ATE305001T1 (de) | Propansäure-derivate als integrin-rezeptor- antagonisten | |
| DE60207399D1 (de) | Alkoxycarbonylaminobenzoesäure- oder alkoxycarbonylaminotetrazolylphenylderivate als ip-antagonisten | |
| DE50100358D1 (de) | Neue N-Triazolylmethyl-Piperazinderivate als Neurokininrezeptor-Antagonisten | |
| NO20020644D0 (no) | Nye integrinreseptor-antagonister | |
| DE60017110D1 (de) | Biphenylderivate als neurokinin-1 antagonisten | |
| AU2002220598A1 (en) | Beta-amino acid derivatives as integrin receptor antagonists | |
| ATE321041T1 (de) | Alkoxycarbonylamino-heteroaryl- carbonsäurederivate als ip-antagonisten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |